Bellerophon Therapeutics LLC (Nasdaq: BLPH) reported upbeat interim results from a Phase 2 long-term extension study of INOplus to treat pulmonary arterial hypertension. The stock price leaped $2.50 to $6.22.
Upbeat interim study results for Bellerophon Therapeutics
September 25, 2015 at 20:45 PM EDT
